Viral Vaccine Cell Culture Media Market, 2022-2035

Viral Vaccine Cell Culture Media Market, 2022-2035

Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.

Vaccine production is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for the manufacturing of vaccines. As a matter of fact, the recent surge in demand for vaccines amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.

The “Viral Vaccine Cell Culture Media Market Distribution by [A] Type of Cell Culture (Adherent and Suspension), [B] Type of Media (Animal Component Free, Protein Free and Serum Free), [C] Scale of Operation (Clinical Operations and Commercial Operations), [D] Type of End-User (Industry Players and Non-Industry Players), and [E] Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035 ” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:
A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).
Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.

One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, Medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Who are the key players engaged in the development of viral vaccine cell culture media?
Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
What type of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the relative competitiveness of different viral vaccine cell culture media?
Who are the most likely partners for vaccine cell culture media developers?
What are the key challenges currently faced by stakeholders in this industry?
What are the anticipated future trends related to viral vaccine cell culture media developers?
How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Who are the key players engaged in the development of viral vaccine cell culture media?
Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
What type of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the relative competitiveness of different viral vaccine cell culture media?
Who are the most likely partners for vaccine cell culture media developers?
What are the key challenges currently faced by stakeholders in this industry?
What are the anticipated future trends related to viral vaccine cell culture media developers?
How is the current and future market opportunity likely to be distributed across key market segments?

1.2. CHAPTER OUTLINES
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of viral vaccine cell culture media market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to vaccine cell culture media. It further includes a detailed discussion on the vaccine components, historical evolution and development of viral vaccines, along with information on the types of viral vaccine, cell culture and cell culture media. Furthermore, it provides a brief overview of the advantages offered by cell culture media and their key limitations.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, HEK cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).

Chapter 5 features elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 6 provides detailed analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.

Chapter 7 features an in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.

Chapter 8 features an in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.

Chapter 10 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 2800 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 provides an informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.

Chapter 12 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussion(s) that were held key stakeholders in the industry.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 2BScientific
2. Adimmune
3. Aduro Biotech
4. Advagene Biopharma
5. Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
6. Advanced BioScience Laboratories
7. Advent
8. AJ Biologics
9. Albany Molecular Research
10. Alopexx Vaccine
11. Altimmune
12. Amphera
13. Anhui Zhifei Longcom Biologic Pharmacy
14. Applied Biosystems
15. Argos Therapeutics
16. Astellas Pharma
17. Asterias Biotherapeutics
18. ATZ labs
19. Auro Vaccines
20. Aurora Biopharma
21. AVAX Technologies
22. Avid Bioservices
23. AVIR Green Hills Biotechnology
24. Batavia Biosciences
25. Bavarian Nordic
26. BD Biosciences
27. Beijing Minhai Biotechnology
28. Beijing Zhifei Lvzhu Biopharmaceutical
29. Bharat Biotech
30. Bielefeld University
31. Bio Farma
32. BioCell
33. BioConnection
34. Biofabri
35. Biological E
36. Biological Industries
37. BioMARC
38. BioReliance
39. BlueWillow Biologics
40. Boehringer Ingelheim
41. Boryung Pharmaceutical
42. BravoVax
43. Bryllan
44. CanSino Biologics
45. Capricorn Scientific
46. Catalent Biologics
47. Cellca (Acquired by Sartorius)
48. CellGenix
49. CEVEC Pharmaceuticals
50. Charles River Laboratories
51. Chengdu Zenmindes Biotechnology
52. CiMaas
53. CJ HealthCare
54. Cobra Biologics
55. Codagenix
56. Commonwealth Serum Laboratories (CSL)
57. Creative Biolabs
58. Curevo Vaccine
59. Cytiva
60. CyTuVax
61. Daiichi Sankyo
62. DanDrit Biotech
63. DCPrime
64. Dendreon
65. Elios Therapeutics
66. Emergent BioSolutions
67. Fisher Scientific (Acquired by Thermo Fisher Scientific)
68. FluGen
69. FUJIFILM Wako Pure Chemicals
70. GC Pharma
71. GeneOne Life Science
72. GlaxoSmithKline
73. Gradalis
74. HALIX
75. Heat Biologics
76. Hilleman Laboratories
77. Hookipa Biotech
78. Icahn School of Medicine at Mount Sinai
79. IDT Biologika
80. ILiAD Biotechnologies
81. Immunicum
82. ImmunoCellular Therapeutics
83. Immutep
84. Indian Immunologicals
85. Inovio Pharmaceuticals
86. Institut National de la Santé et de la Recherche Médicale (INSERM)
87. Insud Pharma
88. Intermountain Life Sciences
89. Intervet
90. InVitria
91. Invitrogen
92. Irvine Scientific Sales (Acquired by FUJIFILM)
93. IS JAPAN (Acquired by FUJIFILM)
94. Janssen Pharmaceuticals
95. Jianshun Biosciences
96. JN International Medical
97. JW CreaGene
98. Kansas State University
99. KBI Biopharma
100. Kiromic
101. Leland Stanford Junior University
102. LG Chem
103. LimmaTech Biologics
104. Lonza
105. Luina Bio
106. Massachusetts Institute of Technology
107. MassBiologics
108. Medicago
109. Medigen Vaccine Biologics
110. Medigene
111. Meissa Vaccines
112. Merck
113. Meridian Life Science
114. MilliporeSigma
115. MinervaX
116. Moderna
117. MolecuVax
118. Northwest Biotherapeutics
119. Nova Immunotherapeutics
120. Novartis
121. Novasep
122. Novavax
123. NPO Petrovax Pharm
124. Ology Bioservices
125. Oncobiomed
126. OPM Biosciences
127. Osivax
128. Oxford Biomedica
129. Pall Corporation
130. Panacea Biotec
131. Patheon Viral Vector Services
132. PDC*line Pharma
133. Pfizer
134. Premas Biotech
135. Prestige BioPharma
136. ProBioGen
137. Regeneus
138. Research Institute at Nationwide Children's Hospital
139. Sanaria
140. Sanofi Pasteur
141. Saronic Biotechnology
142. Sartorius
143. Scandinavian Biopharma
144. Seqirus
145. Serum Institute of India
146. Shanghai Bovax Biotechnology
147. Shenzhen Hornetcorn Biotechnology
148. Shenzhen Kangtai Biological Products
149. Sigma-Aldrich
150. SK Bioscience
151. SOTIO
152. Symbiosis Pharmaceutical Services
153. Takeda
154. TapImmune
155. Tella
156. Tessa Therapeutics
157. TeutoCell
158. Themis Bioscience
159. Thermo Electron
160. Thermo Fisher Scientific
161. Thousand Oaks Biopharmaceuticals
162. TNCbio
163. Unity Lab Services
164. University of California
165. University of Pennsylvania
166. University of Texas
167. USHEALTH
168. Vaccinogen
169. Vaccitech
170. Valneva
171. Vaxart
172. Vaxine
173. Vibalogics
174. Waisman Biomanufacturing
175. WuXi Biologics
176. Xell
177. XEME Biopharma

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.